LMO2 is part of the LIM-only family of proteins which has four members (LMO1-4) that are implicated in a variety of cancers. LMO2 is linked to diffuse large B cell lymphoma (DLBCL) and prostate cancer (1). LMO2 protein is a nuclear marker, expressed in normal germinal-center (GC) B cells and in a subset of GC-derived B-cell lymphomas. LMO2 is also expressed in bone marrow hematopoietic precursors and endothelial cells (2). By immunohistochemistry (IHC) staining, LMO2 displays a crisp nuclear localization that allows for easier interpretation of the stain on paraffin sections in comparison to the diffuse cytoplasmic staining pattern of Human Germinal center Associated Lymphoma (HGAL) (3). LMO2 serves as one of the best prognostic markers of longer survival following immunochemotherapy for DLBCL patients. Additionally, LMO2 expression in DLBCL cells results in genomic instability, which suggests that LMO2 may affect DNA repair efficiency and potentially exploited as a biomarker to stratify patients for therapy (4).